Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

318 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Helicobacter pylori virulence factors--one part of a big picture.
Höcker M, Hohenberger P. Höcker M, et al. Lancet. 2003 Oct 11;362(9391):1231-3. doi: 10.1016/S0140-6736(03)14547-3. Lancet. 2003. PMID: 14568748
Gastric cancer.
Hohenberger P, Gretschel S. Hohenberger P, et al. Lancet. 2003 Jul 26;362(9380):305-15. doi: 10.1016/s0140-6736(03)13975-x. Lancet. 2003. PMID: 12892963 Review.
Adjuvant imatinib in GIST: a self-fulfilling prophecy, or more?
Hohenberger P. Hohenberger P. Lancet. 2009 Mar 28;373(9669):1058-60. doi: 10.1016/S0140-6736(09)60562-6. Epub 2009 Mar 18. Lancet. 2009. PMID: 19303138 No abstract available.
Gastrointestinal stromal tumour.
Joensuu H, Hohenberger P, Corless CL. Joensuu H, et al. Lancet. 2013 Sep 14;382(9896):973-83. doi: 10.1016/S0140-6736(13)60106-3. Epub 2013 Apr 24. Lancet. 2013. PMID: 23623056 Review.
Outcome analysis of 189 consecutive cancer patients referred to the intensive care unit as emergencies during a 2-year period.
Maschmeyer G, Bertschat FL, Moesta KT, Häusler E, Held TK, Nolte M, Osterziel KJ, Papstein V, Peters M, Reich G, Schmutzler M, Sezer O, Stula M, Wauer H, Wörtz T, Wischnewsky M, Hohenberger P. Maschmeyer G, et al. Eur J Cancer. 2003 Apr;39(6):783-92. doi: 10.1016/s0959-8049(03)00004-2. Eur J Cancer. 2003. PMID: 12651204
Management of small gastrointestinal stromal tumours - Authors' reply.
Joensuu H, Hohenberger P. Joensuu H, et al. Lancet. 2013 Nov 23;382(9906):1701-2. doi: 10.1016/S0140-6736(13)62398-3. Lancet. 2013. PMID: 24267995 No abstract available.
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR. Schöffski P, et al. Lancet. 2016 Apr 16;387(10028):1629-37. doi: 10.1016/S0140-6736(15)01283-0. Epub 2016 Feb 10. Lancet. 2016. PMID: 26874885 Clinical Trial.
Overall survival was significantly improved in patients assigned to eribulin compared with those assigned to dacarbazine (median 13·5 months [95% CI 10·9-15·6] vs 11·5 months [9·6-13·0]; hazard ratio 0·77 [95% CI 0·62-0·95]; p=0·0169). ...
Overall survival was significantly improved in patients assigned to eribulin compared with those assigned to dacarbazine (median 13·5 months …
A start towards immunotherapy in sarcomas?
Hohenberger P. Hohenberger P. Lancet Oncol. 2018 Mar;19(3):283-285. doi: 10.1016/S1470-2045(18)30039-1. Epub 2018 Jan 19. Lancet Oncol. 2018. PMID: 29370991 No abstract available.
Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib.
Kasper B, Dimitrakopoulou-Strauss A, Strauss LG, Hohenberger P. Kasper B, et al. Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):1876-82. doi: 10.1007/s00259-010-1498-x. Epub 2010 Jun 19. Eur J Nucl Med Mol Imaging. 2010. PMID: 20559633 Clinical Trial.
318 results
Jump to page
Feedback